CLL Therapy Duration: How Age and Risk Shape Treatment Choice

While results from the CLL17 trial (NCT04608318) suggest comparable efficacy across several modern frontline regimens for chronic lymphocytic leukemia (CLL), treatment duration decisions still require individualized discussions with patients. In an interview with Targeted Oncology, Nicole Lamanna, MD, hematologist/oncologist at Columbia University Irving Medical Center, discusses how patient preferences, age, and disease risk influence her choice of continuous or fixed-duration therapy.

Watch part 1 of the interview with Dr Lamanna.

Lamanna noted that because progression-free survival and overall survival appear similar across modern approaches in CLL17, conversations with patients often focus on lifestyle considerations. Some patients prefer time-limited therapy, which allows them to stop treatment after a defined course and potentially enjoy a treatment-free interval before requiring therapy again. Others favor the simplicity of continuous therapy, particularly if they are already managing multiple medications and prefer a regimen with less intensive monitoring or fewer clinic visits.

From a clinical perspective, patient age can also influence treatment recommendations. Lamanna said she often leans toward fixed-duration therapy for younger patients with CLL because they are likely to require multiple lines of therapy over their lifetime. Using time-limited approaches may allow clinicians to preserve future treatment options and potentially reuse effective agents later. In contrast, continuous treatment with a Bruton tyrosine kinase inhibitor can control disease for years but may eventually lead to drug resistance, limiting the ability to reuse that therapy.

Risk stratification remains another important factor. For patients with higher-risk disease features such as TP53 alterations or 17p deletion, Lamanna said she may still favor continuous therapy or enrollment in a clinical trial exploring longer-duration or combination approaches, including potential triplet regimens.

Ultimately, Lamanna emphasized that both strategies remain highly effective in the frontline setting. Her advice is to review the advantages and trade-offs of continuous vs time-limited therapy while considering patient age, genomic risk factors, and personal treatment goals to guide shared decision-making in CLL care.